Gene replacement therapy using the AAV9/hSURF1 vector in patients with LS with SURF1 mutations has obtained an orphan drug designation by EMA (EU/3/21/2531) after proving successful in SURF1 knockout mice [98]. This evidence concerns the gene SURF1 and Leigh syndrome.